array(40) {
  [0]=>
  string(4) "1751"
  ["article_id"]=>
  string(4) "1751"
  [1]=>
  string(160) "Genentech to Discontinue Phase III CREAD 1 and 2 Clinical Studies of Crenezumab in Early Alzheimer’s Disease (AD) - Other Company Programs in AD Continue"
  ["article_title"]=>
  string(160) "Genentech to Discontinue Phase III CREAD 1 and 2 Clinical Studies of Crenezumab in Early Alzheimer’s Disease (AD) - Other Company Programs in AD Continue"
  [2]=>
  string(150) "South San Francisco, CA -- January 29, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the decision to di"
  ["short_description"]=>
  string(150) "South San Francisco, CA -- January 29, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the decision to di"
  [3]=>
  string(245) "South San Francisco, CA -- January 29, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the decision to discontinue CREAD 1 and CREAD 2 (BN29552 and BN29553) Phase III studies of the investigational..."
  ["description"]=>
  string(245) "South San Francisco, CA -- January 29, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the decision to discontinue CREAD 1 and CREAD 2 (BN29552 and BN29553) Phase III studies of the investigational..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/genentech-discontinue-phase-iii-cread-1-2-clinical-studies-crenezumab-early-alzheimer-s-ad-other-18069.html?utm_source=ddc&utm_medium=rss&utm_campaign=Genentech+to+Discontinue+Phase+III+CREAD+1+and+2+Clinical+Studies+of+Crenezumab+in+Early+Alzheimer%E2%80%99s+Di"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/genentech-discontinue-phase-iii-cread-1-2-clinical-studies-crenezumab-early-alzheimer-s-ad-other-18069.html?utm_source=ddc&utm_medium=rss&utm_campaign=Genentech+to+Discontinue+Phase+III+CREAD+1+and+2+Clinical+Studies+of+Crenezumab+in+Early+Alzheimer%E2%80%99s+Di"
  [15]=>
  string(19) "2019-01-29 13:02:12"
  ["add_date"]=>
  string(19) "2019-01-29 13:02:12"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:38"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1707"
  ["article_id"]=>
  string(4) "1707"
  [1]=>
  string(89) "FDA Approves Osphena (ospemifene) for Moderate to Severe Vaginal Dryness Due to Menopause"
  ["article_title"]=>
  string(89) "FDA Approves Osphena (ospemifene) for Moderate to Severe Vaginal Dryness Due to Menopause"
  [2]=>
  string(150) "BLAINVILLE, QC, January 29, 2019 – Duchesnay Inc., a pharmaceutical company specializing in women’s health, announced today that the FDA h"
  ["short_description"]=>
  string(150) "BLAINVILLE, QC, January 29, 2019 – Duchesnay Inc., a pharmaceutical company specializing in women’s health, announced today that the FDA h"
  [3]=>
  string(251) "BLAINVILLE, QC, January 29, 2019 – Duchesnay Inc., a pharmaceutical company specializing in women’s health, announced today that the FDA has approved its supplemental New Drug Application (sNDA) seeking to add moderate to severe vaginal..."
  ["description"]=>
  string(251) "BLAINVILLE, QC, January 29, 2019 – Duchesnay Inc., a pharmaceutical company specializing in women’s health, announced today that the FDA has approved its supplemental New Drug Application (sNDA) seeking to add moderate to severe vaginal..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(255) "https://www.drugs.com/newdrugs/fda-approves-osphena-ospemifene-moderate-severe-vaginal-dryness-due-menopause-4910.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Osphena+%28ospemifene%29+for+Moderate+to+Severe+Vaginal+Dryness+Due+to+Menopause"
  ["blog_url"]=>
  string(255) "https://www.drugs.com/newdrugs/fda-approves-osphena-ospemifene-moderate-severe-vaginal-dryness-due-menopause-4910.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Osphena+%28ospemifene%29+for+Moderate+to+Severe+Vaginal+Dryness+Due+to+Menopause"
  [15]=>
  string(19) "2019-01-29 12:01:33"
  ["add_date"]=>
  string(19) "2019-01-29 12:01:33"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "5308"
  ["article_id"]=>
  string(4) "5308"
  [1]=>
  string(26) "European Statistical Forum"
  ["article_title"]=>
  string(26) "European Statistical Forum"
  [2]=>
  string(150) "In the past years, companies have increased their focus on the oversight and prevention of potential risks impacting individual clinical studies or th"
  ["short_description"]=>
  string(150) "In the past years, companies have increased their focus on the oversight and prevention of potential risks impacting individual clinical studies or th"
  [3]=>
  string(506) "In the past years, companies have increased their focus on the oversight and prevention of potential risks impacting individual clinical studies or the overarching clinical program success by means of subject well-being and protection, data quality and site performance as well as accuracy and correctness of final study results.&#nl&#nlThis change in perspective has been encouraged by regulatory authorities with both FDA and EMA guidelines released in 2013 for risk-based quality management of clinic..."
  ["description"]=>
  string(506) "In the past years, companies have increased their focus on the oversight and prevention of potential risks impacting individual clinical studies or the overarching clinical program success by means of subject well-being and protection, data quality and site performance as well as accuracy and correctness of final study results.&#nl&#nlThis change in perspective has been encouraged by regulatory authorities with both FDA and EMA guidelines released in 2013 for risk-based quality management of clinic..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(58) "https://www.pharmiweb.com/event/european-statistical-forum"
  ["blog_url"]=>
  string(58) "https://www.pharmiweb.com/event/european-statistical-forum"
  [15]=>
  string(19) "2019-01-29 10:39:02"
  ["add_date"]=>
  string(19) "2019-01-29 10:39:02"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-10-31 15:50:28"
  ["create_at"]=>
  string(19) "2019-10-31 15:50:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1708"
  ["article_id"]=>
  string(4) "1708"
  [1]=>
  string(164) "FDA Approves Imbruvica (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia"
  ["article_title"]=>
  string(164) "FDA Approves Imbruvica (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia"
  [2]=>
  string(150) "HORSHAM, Pa., Jan. 28, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Admin"
  ["short_description"]=>
  string(150) "HORSHAM, Pa., Jan. 28, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Admin"
  [3]=>
  string(238) "HORSHAM, Pa., Jan. 28, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of Imbruvica (ibrutinib) in combination with obinutuzumab in..."
  ["description"]=>
  string(238) "HORSHAM, Pa., Jan. 28, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of Imbruvica (ibrutinib) in combination with obinutuzumab in..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-imbruvica-ibrutinib-plus-obinutuzumab-first-non-chemotherapy-combination-regimen-na-ve-4906.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Imbruvica+%28ibrutinib%29+Plus+Obinutuzumab+as+First+Non-Chemotherapy+Combination+Regimen+for+Treatment"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/newdrugs/fda-approves-imbruvica-ibrutinib-plus-obinutuzumab-first-non-chemotherapy-combination-regimen-na-ve-4906.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Imbruvica+%28ibrutinib%29+Plus+Obinutuzumab+as+First+Non-Chemotherapy+Combination+Regimen+for+Treatment"
  [15]=>
  string(19) "2019-01-29 06:01:47"
  ["add_date"]=>
  string(19) "2019-01-29 06:01:47"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2409"
  ["article_id"]=>
  string(4) "2409"
  [1]=>
  string(62) "New Belgian legislation on the distribution of medical devices"
  ["article_title"]=>
  string(62) "New Belgian legislation on the distribution of medical devices"
  [2]=>
  string(150) "Today, the Belgian Minister of Health published the new Royal Decree of 19 December 2018 on the liberalisation of the distribution circuit for medical"
  ["short_description"]=>
  string(150) "Today, the Belgian Minister of Health published the new Royal Decree of 19 December 2018 on the liberalisation of the distribution circuit for medical"
  [3]=>
  string(703) "
Today, the Belgian Minister of Health published the new Royal Decree of 19 December 2018 on the liberalisation of the distribution circuit for medical devices. The Royal Decree forms part of a package of measures for the implementation of Regulation (EU) 2017/745 on medical devices, also known as the Medical Device Regulation. The distribution of
&#nl
The post New Belgian legislation on the distribution of medical devices appeared first on Focus on Regulation.
&#nl"
  ["description"]=>
  string(703) "
Today, the Belgian Minister of Health published the new Royal Decree of 19 December 2018 on the liberalisation of the distribution circuit for medical devices. The Royal Decree forms part of a package of measures for the implementation of Regulation (EU) 2017/745 on medical devices, also known as the Medical Device Regulation. The distribution of
&#nl
The post New Belgian legislation on the distribution of medical devices appeared first on Focus on Regulation.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "101"
  ["rss_id"]=>
  string(3) "101"
  [14]=>
  string(103) "https://www.hlregulation.com/2019/01/28/new-belgian-legislation-on-the-distribution-of-medical-devices/"
  ["blog_url"]=>
  string(103) "https://www.hlregulation.com/2019/01/28/new-belgian-legislation-on-the-distribution-of-medical-devices/"
  [15]=>
  string(19) "2019-01-28 23:22:23"
  ["add_date"]=>
  string(19) "2019-01-28 23:22:23"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:42:28"
  ["create_at"]=>
  string(19) "2019-05-09 16:42:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1737"
  ["article_id"]=>
  string(4) "1737"
  [1]=>
  string(48) "A day in the life of a medication safety officer"
  ["article_title"]=>
  string(48) "A day in the life of a medication safety officer"
  [2]=>
  string(99) "Rajesh Jethwa details a typical day at Mid Essex Hospital NHS Trust as a medication safety officer."
  ["short_description"]=>
  string(99) "Rajesh Jethwa details a typical day at Mid Essex Hospital NHS Trust as a medication safety officer."
  [3]=>
  string(99) "Rajesh Jethwa details a typical day at Mid Essex Hospital NHS Trust as a medication safety officer."
  ["description"]=>
  string(99) "Rajesh Jethwa details a typical day at Mid Essex Hospital NHS Trust as a medication safety officer."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "12"
  ["rss_id"]=>
  string(2) "12"
  [14]=>
  string(153) "https://www.pharmaceutical-journal.com/careers-and-jobs/careers-and-jobs/career-profile/a-day-in-the-life-of-a-medication-safety-officer/20206032.article"
  ["blog_url"]=>
  string(153) "https://www.pharmaceutical-journal.com/careers-and-jobs/careers-and-jobs/career-profile/a-day-in-the-life-of-a-medication-safety-officer/20206032.article"
  [15]=>
  string(19) "2019-01-28 20:06:00"
  ["add_date"]=>
  string(19) "2019-01-28 20:06:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:37"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1752"
  ["article_id"]=>
  string(4) "1752"
  [1]=>
  string(177) "Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension"
  ["article_title"]=>
  string(177) "Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension"
  [2]=>
  string(150) "DUBLIN, Jan. 28, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today an"
  ["short_description"]=>
  string(150) "DUBLIN, Jan. 28, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today an"
  [3]=>
  string(248) "DUBLIN, Jan. 28, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a registrational Phase 3 clinical trial of ampreloxetine..."
  ["description"]=>
  string(248) "DUBLIN, Jan. 28, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a registrational Phase 3 clinical trial of ampreloxetine..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/theravance-biopharma-announces-first-patient-dosed-registrational-phase-3-study-ampreloxetine-td-18063.html?utm_source=ddc&utm_medium=rss&utm_campaign=Theravance+Biopharma+Announces+First+Patient+Dosed+in+Registrational+Phase+3+Study+of+Ampreloxetine+%28TD-9855%"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/theravance-biopharma-announces-first-patient-dosed-registrational-phase-3-study-ampreloxetine-td-18063.html?utm_source=ddc&utm_medium=rss&utm_campaign=Theravance+Biopharma+Announces+First+Patient+Dosed+in+Registrational+Phase+3+Study+of+Ampreloxetine+%28TD-9855%"
  [15]=>
  string(19) "2019-01-28 09:01:38"
  ["add_date"]=>
  string(19) "2019-01-28 09:01:38"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:38"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1709"
  ["article_id"]=>
  string(4) "1709"
  [1]=>
  string(78) "FDA Approves Tosymra (sumatriptan) Nasal Spray for Acute Treatment of Migraine"
  ["article_title"]=>
  string(78) "FDA Approves Tosymra (sumatriptan) Nasal Spray for Acute Treatment of Migraine"
  [2]=>
  string(150) "January 27, 2019 -- Dr. Reddy’s Laboratories Ltd. and its subsidiary, Promius Pharma, LLC today announced the approval of Tosymra (previously kn"
  ["short_description"]=>
  string(150) "January 27, 2019 -- Dr. Reddy’s Laboratories Ltd. and its subsidiary, Promius Pharma, LLC today announced the approval of Tosymra (previously kn"
  [3]=>
  string(250) "January 27, 2019 -- Dr. Reddy’s Laboratories Ltd. and its subsidiary, Promius Pharma, LLC today announced the approval of Tosymra (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA). Tosymra is indicated for the acute..."
  ["description"]=>
  string(250) "January 27, 2019 -- Dr. Reddy’s Laboratories Ltd. and its subsidiary, Promius Pharma, LLC today announced the approval of Tosymra (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA). Tosymra is indicated for the acute..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(220) "https://www.drugs.com/newdrugs/fda-approves-tosymra-sumatriptan-nasal-acute-migraine-4909.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Tosymra+%28sumatriptan%29+Nasal+Spray+for+Acute+Treatment+of+Migraine"
  ["blog_url"]=>
  string(220) "https://www.drugs.com/newdrugs/fda-approves-tosymra-sumatriptan-nasal-acute-migraine-4909.html?utm_source=ddc&utm_medium=rss&utm_campaign=FDA+Approves+Tosymra+%28sumatriptan%29+Nasal+Spray+for+Acute+Treatment+of+Migraine"
  [15]=>
  string(19) "2019-01-27 10:01:32"
  ["add_date"]=>
  string(19) "2019-01-27 10:01:32"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:34"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1738"
  ["article_id"]=>
  string(4) "1738"
  [1]=>
  string(57) "A trigger for change? Two years on from the Carter review"
  ["article_title"]=>
  string(57) "A trigger for change? Two years on from the Carter review"
  [2]=>
  string(157) "In Lord Carter’s 2016 review, he advised acute hospitals to deploy more clinical pharmacists and use them to drive value from the £6.7bn that hospi"
  ["short_description"]=>
  string(157) "In Lord Carter’s 2016 review, he advised acute hospitals to deploy more clinical pharmacists and use them to drive value from the £6.7bn that hospi"
  [3]=>
  string(307) "In Lord Carter’s 2016 review, he advised acute hospitals to deploy more clinical pharmacists and use them to drive value from the £6.7bn that hospitals spend on medicines every year. Two years on, The Pharmaceutical Journal investigates whether trusts are on track to meet these ambitious targets."
  ["description"]=>
  string(307) "In Lord Carter’s 2016 review, he advised acute hospitals to deploy more clinical pharmacists and use them to drive value from the £6.7bn that hospitals spend on medicines every year. Two years on, The Pharmaceutical Journal investigates whether trusts are on track to meet these ambitious targets."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "12"
  ["rss_id"]=>
  string(2) "12"
  [14]=>
  string(139) "https://www.pharmaceutical-journal.com/news-and-analysis/features/a-trigger-for-change-two-years-on-from-the-carter-review/20205958.article"
  ["blog_url"]=>
  string(139) "https://www.pharmaceutical-journal.com/news-and-analysis/features/a-trigger-for-change-two-years-on-from-the-carter-review/20205958.article"
  [15]=>
  string(19) "2019-01-26 00:19:00"
  ["add_date"]=>
  string(19) "2019-01-26 00:19:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:37"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:37"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2410"
  ["article_id"]=>
  string(4) "2410"
  [1]=>
  string(95) "European Commission publishes factsheet on the (in vitro) medical devices procurement ecosystem"
  ["article_title"]=>
  string(95) "European Commission publishes factsheet on the (in vitro) medical devices procurement ecosystem"
  [2]=>
  string(150) "Introduction The European Commission has published a factsheet addressed to organisers of public tenders involving medical devices. The goal of the fa"
  ["short_description"]=>
  string(150) "Introduction The European Commission has published a factsheet addressed to organisers of public tenders involving medical devices. The goal of the fa"
  [3]=>
  string(814) "
Introduction The European Commission has published a factsheet addressed to organisers of public tenders involving medical devices. The goal of the factsheet is to provide hospitals, clinics, ministries and competent authorities responsible for the procurement of (in vitro) medical devices with guidance concerning Medical Device Regulation (MDR) and the In Vitro Device Regulation (IVDR). This
&#nl
The post European Commission publishes factsheet on the (in vitro) medical devices procurement ecosystem appeared first on Focus on Regulation.
&#nl"
  ["description"]=>
  string(814) "
Introduction The European Commission has published a factsheet addressed to organisers of public tenders involving medical devices. The goal of the factsheet is to provide hospitals, clinics, ministries and competent authorities responsible for the procurement of (in vitro) medical devices with guidance concerning Medical Device Regulation (MDR) and the In Vitro Device Regulation (IVDR). This
&#nl
The post European Commission publishes factsheet on the (in vitro) medical devices procurement ecosystem appeared first on Focus on Regulation.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "101"
  ["rss_id"]=>
  string(3) "101"
  [14]=>
  string(134) "https://www.hlregulation.com/2019/01/25/european-commission-publishes-factsheet-on-the-in-vitro-medical-devices-procurement-ecosystem/"
  ["blog_url"]=>
  string(134) "https://www.hlregulation.com/2019/01/25/european-commission-publishes-factsheet-on-the-in-vitro-medical-devices-procurement-ecosystem/"
  [15]=>
  string(19) "2019-01-25 18:49:11"
  ["add_date"]=>
  string(19) "2019-01-25 18:49:11"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-09 16:42:28"
  ["create_at"]=>
  string(19) "2019-05-09 16:42:28"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1753"
  ["article_id"]=>
  string(4) "1753"
  [1]=>
  string(163) "Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease"
  ["article_title"]=>
  string(163) "Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease"
  [2]=>
  string(150) "WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals"
  ["short_description"]=>
  string(150) "WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals"
  [3]=>
  string(249) "WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced the..."
  ["description"]=>
  string(249) "WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced the..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/proteon-therapeutics-announces-publication-results-phase-3-patency-1-clinical-trial-investigational-18064.html?utm_source=ddc&utm_medium=rss&utm_campaign=Proteon+Therapeutics+Announces+Publication+of+Results+from+Phase+3+PATENCY-1+Clinical+Trial+of+Investigation"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/proteon-therapeutics-announces-publication-results-phase-3-patency-1-clinical-trial-investigational-18064.html?utm_source=ddc&utm_medium=rss&utm_campaign=Proteon+Therapeutics+Announces+Publication+of+Results+from+Phase+3+PATENCY-1+Clinical+Trial+of+Investigation"
  [15]=>
  string(19) "2019-01-24 10:01:29"
  ["add_date"]=>
  string(19) "2019-01-24 10:01:29"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:38"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "1754"
  ["article_id"]=>
  string(4) "1754"
  [1]=>
  string(127) "Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab"
  ["article_title"]=>
  string(127) "Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab"
  [2]=>
  string(150) "THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a"
  ["short_description"]=>
  string(150) "THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a"
  [3]=>
  string(243) "THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a Phase 1/ Phase 3 study evaluating the pharmacokinetics, efficacy and safety of biosimilar..."
  ["description"]=>
  string(243) "THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a Phase 1/ Phase 3 study evaluating the pharmacokinetics, efficacy and safety of biosimilar..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/amgen-allergan-announce-positive-top-line-results-phase-1-phase-3-study-abp-798-biosimilar-18062.html?utm_source=ddc&utm_medium=rss&utm_campaign=Amgen+And+Allergan+Announce+Positive+Top-Line+Results+From+Phase+1%2F+Phase+3+Study+Of+ABP+798%2C+Biosimilar+Candidat"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/amgen-allergan-announce-positive-top-line-results-phase-1-phase-3-study-abp-798-biosimilar-18062.html?utm_source=ddc&utm_medium=rss&utm_campaign=Amgen+And+Allergan+Announce+Positive+Top-Line+Results+From+Phase+1%2F+Phase+3+Study+Of+ABP+798%2C+Biosimilar+Candidat"
  [15]=>
  string(19) "2019-01-24 09:01:07"
  ["add_date"]=>
  string(19) "2019-01-24 09:01:07"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-02-15 20:39:38"
  ["create_at"]=>
  string(19) "2019-02-15 20:39:38"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}